Preventive effects of Haishe capsules on the conversion of amnestic mild cognitive impairment to Alzheimer's disease
10.3760/cma.j.issn.0254-9026.2017.03.013
- VernacularTitle:复方海蛇胶囊预防遗忘型轻度认知功能障碍向阿尔茨海默病转化效果的研究
- Author:
Enyan YU
;
Zhengluan LIAO
;
Yunfei TAN
;
Yaju QIU
;
Junpeng ZHU
;
Meifang SHI
;
Hong WANG
;
Yan CHEN
;
Sisi LIN
;
Minghao WU
- Keywords:
Mild cognitive impairment;
Alzheimer's disease;
Haishe capsules
- From:
Chinese Journal of Geriatrics
2017;36(3):278-281
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the preventive effects of Haishe capsules on the conversion of amnestic mild cognitive impairment (aMCI) to Alzheimer's disease(AD).Methods Patients (n=120) with aMCI from our department were recruited and randomly divided into the treatment group and the control group (n=60 in each group).The treatment group was given 0.9 gram of Haishe capsules three times a day while the control group received no drug treatment.Data on the conversion ratio,memory and cognitive function were comparedbetween the groups in a 24-months follow-up.Results By the end of the study,12 patients in the treatment group and 15 in the control group dropped out.Valid data for 93 patients were available for statistical analysis (48 in the treatment group and 45 in the control group).The number of aMCI patients who converted to AD was 6,with a conversion ratio of 12.5％ (6/48);and the number of patients who went through conversion in the control group was 13,with a conversion ratio of 28.8％ (13/45).The difference in conversion between the two groups was statistically significant (x2 =3.83,P＜0.05).After 24 months,MMSE scores for the treatment group (25.52± 1.07) had no significant change compared with baseline levels,while MMSE scores for the control group decreased significantly(24.75--1.49) and were markedly lower than thosefor the treatment group (t=2.85,P＜0.05).MoCA scores for the treatment group (19.39 ±2.01) did not show decline until the end of the study,while those for the control group started to decrease about half way through the study and were lower than scores for the treatment group (t =2.41,P＜0.05).Compared with baseline levels,ADAS-Cogscores for the treatment group (7.62± 1.06) did not increase significantly during the course of the study.ADAS-Cogscores forthe control group were higher at both half way (7.70±0.75) and the end of the study (8.18±0.80)than base line levels,and there was a statistically significant difference in end-of-study ADAS-Cog scores between the two groups(t =-2.6,P＜ 0.05).Conclusions Haishe capsules not only effectively maintain memory and cognitive function,but also delay the conversion from aMCI to AD.
